Xeris Biopharma (XERS) Short Interest Ratio & Short Volume → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free XERS Stock Alerts $1.90 +0.01 (+0.53%) (As of 05/14/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Xeris Biopharma Short Interest DataCurrent Short Volume9,640,000 sharesPrevious Short Volume8,940,000 sharesChange Vs. Previous Month+7.83%Dollar Volume Sold Short$16.87 millionShort Interest Ratio / Days to Cover5.2Last Record DateApril 30, 2024Outstanding Shares148,256,000 sharesPercentage of Shares Shorted6.50%Today's Trading Volume1,692,864 sharesAverage Trading Volume2,015,719 sharesToday's Volume Vs. Average84% Short Selling Xeris Biopharma ? Sign up to receive the latest short interest report for Xeris Biopharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatXERS Short Interest Over TimeXERS Days to Cover Over TimeXERS Percentage of Float Shorted Over Time Ad Porter & CompanyAmerica’s worst nightmare?What This Group Has Planned for the 2024 Election Will Shock You Controversial new exposé reveals what’s really going on in America, what it means for your money, and what you must do to protect your assets before it’s too late.Click here to watch this bombshell exposé now. Xeris Biopharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20249,640,000 shares $16.87 million +7.8%N/A5.2 $1.75 4/15/20248,940,000 shares $16.54 million -0.5%N/A4.8 $1.85 3/31/20248,980,000 shares $19.85 million -2.8%N/A4 $2.21 3/15/20249,240,000 shares $20.61 million -4.2%N/A4 $2.23 2/29/20249,640,000 shares $29.64 million +2.3%N/A4.2 $3.08 2/15/20249,420,000 shares $30.24 million +0.2%N/A4.6 $3.21 Get the Latest News and Ratings for XERS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter. 1/31/20249,400,000 shares $23.12 million -9.7%N/A4.7 $2.46 1/15/202410,410,000 shares $28.84 million +8.3%N/A5.5 $2.77 12/31/20239,610,000 shares $22.58 million +18.4%N/A6.6 $2.35 12/15/20238,120,000 shares $16.40 million -1.2%N/A6.2 $2.02 11/30/20238,220,000 shares $15.29 million -8.2%N/A7 $1.86 11/15/20238,950,000 shares $13.16 million +14.9%N/A8.1 $1.47 10/31/20237,790,000 shares $14.26 million +2.4%N/A8.4 $1.83 10/15/20237,610,000 shares $12.02 million -4.0%N/A8 $1.58 9/30/20237,930,000 shares $14.75 million +0.6%N/A8.4 $1.86 9/15/20237,880,000 shares $15.76 million +6.2%N/A7.5 $2.00 8/31/20237,420,000 shares $16.84 million -12.9%N/A6.9 $2.27 8/15/20238,520,000 shares $19.00 million +2.7%N/A7.8 $2.23 7/31/20238,300,000 shares $21.66 million -2.6%N/A7.1 $2.61 7/15/20238,520,000 shares $21.64 million +0.4%N/A7.2 $2.54 6/30/20238,490,000 shares $22.24 million -5.0%N/A6.5 $2.62 6/15/20238,940,000 shares $24.23 million +13.6%N/A6.7 $2.71 5/31/20237,870,000 shares $20.15 million -5.5%N/A6.2 $2.56 5/15/20238,330,000 shares $23.66 million -1.9%N/A6.3 $2.84 4/30/20238,490,000 shares $19.19 million +6.3%N/A6.9 $2.26 4/15/20237,990,000 shares $17.34 million +2.0%N/A7 $2.17 3/31/20237,830,000 shares $12.76 million -5.4%N/A6.7 $1.63 3/15/20238,280,000 shares $10.76 million +20.9%N/A7.6 $1.30 2/28/20236,850,000 shares $9.45 million +13.4%N/A6.9 $1.38 2/15/20236,040,000 shares $7.61 million -6.9%N/A6.8 $1.26 1/31/20236,490,000 shares $8.05 million +9.1%N/A7.7 $1.24 1/15/20235,950,000 shares $7.62 million +1.9%N/A6.8 $1.28 12/30/20225,840,000 shares $7.77 million +2.5%N/A6.5 $1.33 12/15/20225,700,000 shares $7.64 million -0.7%N/A7.3 $1.34 11/30/20225,740,000 shares $8.61 million -9.5%N/A7 $1.50 11/15/20226,340,000 shares $8.81 million +0.8%N/A7.7 $1.39 10/31/20226,290,000 shares $10.06 million +0.8%N/A7.6 $1.60 10/15/20226,240,000 shares $7.61 million -5.5%N/A7.2 $1.22 9/30/20226,600,000 shares $10.30 million -21.6%N/A8 $1.56 9/15/20228,420,000 shares $15.07 million -8.1%N/A8 $1.79The 2024 Gold Rush: Unleashing Market Potential (Ad)Welcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. XERS Short Interest - Frequently Asked Questions What is Xeris Biopharma's current short interest? Short interest is the volume of Xeris Biopharma shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 9,640,000 shares of XERS short. Learn More on Xeris Biopharma's current short interest. What is a good short interest ratio for Xeris Biopharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. XERS shares currently have a short interest ratio of 5.0. Learn More on Xeris Biopharma's short interest ratio. Is Xeris Biopharma's short interest increasing or decreasing? Xeris Biopharma saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 9,640,000 shares, an increase of 7.8% from the previous total of 8,940,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Xeris Biopharma's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Xeris Biopharma: CytomX Therapeutics, Inc. (4.62%), XBiotech Inc. (3.88%), Enanta Pharmaceuticals, Inc. (14.15%), RAPT Therapeutics, Inc. (9.23%), Nektar Therapeutics (1.99%), Eliem Therapeutics, Inc. (0.31%), Inozyme Pharma, Inc. (8.23%), XOMA Co. (2.33%), Verastem, Inc. (3.49%), Design Therapeutics, Inc. (9.06%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Xeris Biopharma stock? Short selling XERS is an investing strategy that aims to generate trading profit from Xeris Biopharma as its price is falling. XERS shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Xeris Biopharma? A short squeeze for Xeris Biopharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of XERS, which in turn drives the price of the stock up even further. How often is Xeris Biopharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including XERS, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: CTMX Short Interest Data XBIT Short Interest Data ENTA Short Interest Data RAPT Short Interest Data NKTR Short Interest Data ELYM Short Interest Data INZY Short Interest Data XOMA Short Interest Data VSTM Short Interest Data DSGN Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:XERS) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersCharles Payne Demystifies OptionsUnstoppable ProsperityThe A.I. story nobody is telling you (Read ASAP)TradeSmith